Evidence map›Paper›PMID 21954944›Full record

ArticleThe Biochemical journal2011

Targeting tumour cells at the entrance.

Stefan Bröer

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Biochemical journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.Advances in experimental medicine and biology · 2021
    Review
  2. European journal of nuclear medicine and molecular imaging · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stefan BröerResearch School of Biology, Australian National University, Canberra, ACT 0200, Australia. stefan.broer@anu.edu.au
Australian National University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolism in tumour cells is adapted to the demands of a growing cell. The Warburg effect and increased use of glutamine are two well-known adaptations of tumour metabolism. Both require transporters to allow uptake of substrates and efflux of products. Differentiated cells are less reliant on these pathways and as a result are less vulnerable to drugs that curtail nutrient uptake. Thus drugs that reduce nutrient uptake are promising candidates for tumour therapy. Detailed understanding of tumour cell biology will allow the generation of new chemotherapeutic drugs with limited side effects.

Indexed as

AnimalsCarrier ProteinsDown-RegulationSphingolipidsCarrier ProteinsSphingolipids

Identifiers

PMID21954944
OpenAlexW1974414286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.